title: Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer.
abstract: BACKGROUND
  We investigated whether a new marker of bone turnover, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), could be useful in the assessment of bone metastasis and in monitoring of the response to treatment in patients with prostate cancer with bone metastasis.
  
  
  METHODS
  In all, 58 patients with prostate cancer (25 with bone metastasis and 33 without bone metastasis) and 52 patients with benign prostate hypertrophy who were treated between June 1994-August 1997 were included in this study. All patients were newly diagnosed.
  
  
  RESULTS
  Serum ICTP levels in patients with prostate cancer with bone metastasis were significantly higher than those in patients with prostate cancer without bone metastasis (P<0.0001) or with benign prostate hypertrophy (P<0.0001). No significant differences were observed in serum ICTP levels between patients with prostate cancer without bone metastasis and those with benign prostate hypertrophy. Serum ICTP levels correlated significantly with Soloway's grading system for bone scans. Serum ICTP levels in patients with bone metastasis showed a significant downward trend in response to hormonal treatment.
  
  
  CONCLUSIONS
  The determination of serum ICTP levels is useful in the assessment of bone metastasis and in monitoring the response of bone metastasis to treatment to prostate cancer.
authors.affiliation: Department of Urology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Koga
authors.forename: S
authors.initials: S
authors.lastname: Naito
authors.forename: S
authors.initials: S
authors.lastname: Koto
authors.forename: N
authors.initials: N
authors.lastname: Sakamoto
authors.forename: M
authors.initials: M
authors.lastname: Nakashima
authors.forename: T
authors.initials: T
authors.lastname: Yamasaki
authors.forename: H
authors.initials: H
authors.lastname: Noma
authors.forename: J
authors.initials: J
authors.lastname: Kumazawa
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D001859:Bone Neoplasms / Q000097:blood* / Q000556:secondary*; D003094:Collagen / Q000097:blood*; D024042:Collagen Type I; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000097:blood*; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology*
chemical_list: D015415:Biomarkers; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D003094:Collagen; D017430:Prostate-Specific Antigen